Supreme Court Shakeup Adds Complexity for Healthcare

Prior to Ginsburg's death, the court looked likely to uphold the Affordable Care Act, but without her vote, the path to upholding the law has become more complicated.

With Justice Ruth Bader Ginsburg's death Sept. 18, another layer of complexity has been added to this election year for the healthcare industry. The Supreme Court is scheduled to hear oral arguments on the Affordable Care Act on Nov. 10, a week after the U.S. election. Prior to Ginsburg's death, the court looked likely to uphold the ACA at least along the previous voting lines (5-4), but without her vote, the path to upholding the law just got more complicated, creating the potential for the millions of Americans who gained access to insurance through the ACA to lose that coverage. For now, we are not changing our views on any moats or valuations in the industry, but investors should be aware of the various scenarios that could influence the U.S. healthcare system over the next several weeks.

Importantly, the Supreme Court has a couple of options related to hearing oral arguments on the ACA. First, the court could decide to hear the arguments with only eight justices. In the event of a 4-4 tie, the court could turn the case back to the original district court to decide which parts of the law could be upheld without the individual mandate that is in question. In that case, further appeals of that court's decision-making process could be possible while the ACA remains the law of the land. To avoid such uncertainty related to a potential tie vote, though, the Supreme Court could wait to hear oral arguments until another justice is named to the court, which would lead to a definitive vote.

Despite previous precedent from Republican leadership in the Senate that delayed voting on an Obama nominee in 2016 because it was an election year, President Trump and Senate leadership appear intent on voting on a new justice before the end of the year. If that is the case, there is a chance that a 5-4 vote upholding the ACA could turn to a 5-4 vote against the law, assuming the new justice votes in line with most of the other conservative jurists.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

More in Stocks

About the Author

Julie Utterback, CFA

Senior Equity Analyst
More from Author

Julie Utterback, CFA, is a senior equity analyst, AM Healthcare, for Morningstar*. She focuses on medical technology and service companies. She covers managed care organizations including UnitedHealth, service providers like HCA, medical suppliers such as Baxter, and life sciences companies like Danaher. She is also the chairperson of the equity research team’s capital allocation methodology.

Before joining Morningstar in 2005, Utterback was an equity analyst at State Farm Insurance for several years. Utterback joined Morningstar in 2005 as an equity analyst in the healthcare industry, and initially she primarily covered medical technology companies, including orthopedic device, medical equipment, and cardiac device firms. In 2010, she joined Morningstar's credit research team, initiating coverage of the entire healthcare industry and generally helping the organization expand and maintain its credit coverage across many industries. She held that senior credit analyst role until April 2019, when she returned to the equity team to cover medical technology and service companies.

Utterback holds a bachelor's degree in finance from the University of Illinois Urbana-Champaign’s Gies College of Business. She also holds the Chartered Financial Analyst® designation.

* Morningstar Research Services LLC (“Morningstar”) is a wholly owned subsidiary of Morningstar, Inc

Sponsor Center